CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 35 enrolled
Drug / intervention
SPECT Imaging with 99mTc-Tetrofosmin Research Imagingother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03427749
NCT03427749N/ACompleted

Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve

Ottawa Heart Institute Research Corporation·observational·Posted Feb 9, 2018·Updated Apr 10, 2025

In Brief

An observational study evaluating SPECT Imaging with 99mTc-Tetrofosmin Research Imaging for Coronary Artery Disease. Completed, enrolled 35 participants across 7 sites in 6 countries.

Detailed Summary

Patients will be recruited from those referred to the local site's Diagnostic Imaging Department for SPECT myocardial perfusion imaging (MPI) ,who have an intermediate to high pre-test likelihood of disease (Diamond-Forrester criteria ≥ 30%) and are clinically indicated to have an MBF study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Germany, Italy, Japan, Singapore
CollaboratorsGE Healthcare

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 9, 2018
Enrollment StartOct 12, 2018
Primary CompletionOct 1, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8.4 years ago

Interventions

SPECT Imaging with 99mTc-Tetrofosmin Research Imagingother

This is an observational study; patients will be managed according to the standard clinical care of the local site. Study end will be defined as completion of all SPECT imaging at rest and stress. Studies will be acquired at 6 initial sites with mixed prior experience at MBF imaging, to demonstrate feasibility of use in a clinical setting.